trial

Mindfulness and Cognition in Schizophrenia

NCTId NCT03318640
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 34 (actual)
Sponsored by Centre Hospitalier Universitaire de Saint Etienne
Primary completion 2021-05-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2018-09-11
Primary completion
2021-05-03
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
Mindfulness

Sponsors

Centre Hospitalier Universitaire de Saint EtienneLead Sponsor
Fondation de l'AvenirCollaborator

Investigators

1
Anne GROSSELIN, MDPrincipal Investigator

Sites

1 total
Saint-Etienne, France

Facts & assertions

4 sourced
Enrollment
34
Phase
NA
Primary Completion Date
2021-05-03
Status
TERMINATED
relationships
The graph out of here
drug
Mindfulness
drug
lead_sponsor
Centre Hospitalier Universitaire de Saint Etienne
company
collaborator
Fondation de l'Avenir
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Anne GROSSELIN, MD
person